Vector-borne diseases (VBDs) represent a significant public health challenge in India, contributing significantly to the country's disease burden. With a diverse range of vectors and climatic conditions conducive to their spread, understanding the extent of this issue is critical for healthcare professionals.
VBDs in India encompass a wide range of illnesses, including malaria, dengue, chikungunya, Japanese encephalitis, and lymphatic filariasis. Each of these diseases presents unique challenges in terms of prevention, diagnosis, and treatment, necessitating a comprehensive understanding of their epidemiology and clinical manifestations.
The epidemiology of VBDs in India is complex, influenced by factors like vector ecology, climate, and socio-economic determinants. Malaria alone accounts for a significant proportion of the disease burden, with an estimated 219 million cases globally in 2017, of which India contributed 4%. Additionally, the country reports the highest dengue burden in the world, with an estimated 100 million cases annually.
The management of VBDs in India faces numerous challenges, including inadequate surveillance, limited resources for vector control, and gaps in public awareness. However, opportunities exist in the form of advancements in diagnostic technologies, vaccine development, and integrated vector management strategies. The role of healthcare professionals is pivotal in leveraging these opportunities to mitigate the VBD burden.
Vector-borne diseases pose a significant public health challenge in India, requiring a comprehensive, multi-faceted approach. Healthcare professionals play a crucial role in this endeavor, from enhancing disease surveillance and diagnosis to driving public education efforts. By deepening our understanding of these diseases and their management, we can work towards reducing their impact on India's health landscape.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation